Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 157,448 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 157,448 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $3.64, for a total transaction of $573,110.72. Following the transaction, the chief executive officer now directly owns 3,143,753 shares in the company, valued at $11,443,260.92. This trade represents a 4.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Organogenesis Stock Down 3.6 %

NASDAQ ORGO opened at $3.53 on Friday. The firm’s 50 day moving average price is $3.42 and its 200-day moving average price is $2.98. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 52-week low of $2.16 and a 52-week high of $4.70.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period last year, the business earned $0.02 EPS. On average, equities analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Hedge Funds Weigh In On Organogenesis

Several institutional investors and hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors purchased a new position in Organogenesis during the 3rd quarter worth $36,000. Pallas Capital Advisors LLC acquired a new position in Organogenesis during the second quarter valued at $38,000. Delap Wealth Advisory LLC purchased a new stake in Organogenesis in the second quarter valued at $40,000. Intech Investment Management LLC acquired a new stake in Organogenesis during the 3rd quarter worth about $43,000. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Organogenesis by 4,989.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after buying an additional 15,369 shares during the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.